Wegovy Shortage Nearing Its End, Novo Nordisk Confirms

After six months of intermittent supply disruptions that left patients scrambling to maintain their weight loss regimens, Novo Nordisk has announced that Wegovy (semaglutide 2.4 mg injection) availability is returning to normal across the United States. The company said this week that all dose strengths — from the 0.25 mg starter dose through the 2.4 mg maintenance dose — are shipping at rates sufficient to meet current demand, with consistent nationwide availability expected by the end of April 2026.

The news comes as a significant relief to the estimated 1.5 million Americans currently prescribed Wegovy for chronic weight management, many of whom experienced interruptions in their treatment during the shortage period.

What Caused the Shortage

The Wegovy shortage that began in October 2025 resulted from a convergence of factors. Demand for GLP-1 receptor agonist medications has grown explosively, with prescriptions for semaglutide products (including both Wegovy for weight loss and Ozempic for diabetes) increasing by over 300 percent since 2022.

Novo Nordisk had been investing heavily in manufacturing capacity expansion, but a quality control issue at its Kalundborg, Denmark facility in September 2025 forced a temporary production slowdown. The facility, one of the largest pharmaceutical manufacturing sites in the world, required equipment modifications that reduced output for approximately three months.

Simultaneously, the company was navigating increased regulatory scrutiny of its supply chain following reports of counterfeit semaglutide products entering the gray market — a problem that required additional verification steps and slowed distribution.

How Patients Were Affected

The shortage created a cascade of problems for patients. Those unable to fill their maintenance dose prescriptions faced difficult choices: switch to a lower dose (which often meant regaining some lost weight), try to obtain the medication through compounding pharmacies (raising quality and safety questions), or discontinue treatment entirely.

Physicians reported that some patients who interrupted Wegovy treatment experienced rebound weight gain of 5 to 15 pounds within weeks, along with the return of cravings and appetite levels that the medication had been suppressing. Research has consistently shown that GLP-1 medications require continuous use to maintain their effects, and interruptions can be both physically and psychologically difficult for patients.

"The hardest part was watching patients who had made incredible progress — losing 40, 50, even 80 pounds — start to slide backward through no fault of their own," said Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital.

New Manufacturing Capacity Coming Online

Novo Nordisk has invested over $6 billion in manufacturing expansion since 2023, including a new fill-finish facility in Clayton, North Carolina, that became operational in January 2026. The company has also expanded production at facilities in France and Denmark and established new contract manufacturing partnerships.

The combined effect of these investments is expected to more than double the company's global semaglutide production capacity by the end of 2026. Novo Nordisk CEO Lars Fruergaard Jorgensen told investors during a recent earnings call that the company is "determined to ensure that supply never again falls short of patient need."

The Compounding Pharmacy Controversy

During the shortage, many patients turned to compounding pharmacies that produce custom versions of semaglutide. The FDA has allowed compounding of drugs that are on its official shortage list, but as Wegovy exits shortage status, the legal basis for compounded versions becomes murkier.

Novo Nordisk has been aggressive in pursuing legal action against compounders, arguing that compounded semaglutide lacks the quality controls of the branded product and poses safety risks. The company has filed lawsuits against several compounding pharmacies and telehealth companies that prescribe compounded versions.

Patient advocacy groups find themselves in an uncomfortable middle position, acknowledging quality concerns about compounded products while noting that Wegovy's list price — approximately $1,350 per month — puts the branded medication out of reach for many Americans even when it is in stock.

What Patients Should Do Now

Patients currently on Wegovy should contact their pharmacy to confirm availability of their prescribed dose. Those who interrupted treatment during the shortage should consult their prescriber about the appropriate way to restart — in most cases, this involves a brief re-titration period rather than jumping directly back to the maintenance dose.

Patients who switched to alternative GLP-1 medications (such as Mounjaro or Zepbound) during the shortage should discuss with their physician whether switching back to Wegovy is appropriate, as individual responses to different GLP-1 drugs can vary.